- Home
- CNTB vs QTRX Comparison
CNTB vs QTRX Comparison
Compare CNTB & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | QTRX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.4M | 160.0M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTB | QTRX |
|---|---|---|
| Price | $0.90 | $2.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $5.88 | $3.17 |
| AVG Volume (30 Days) | ★ 1.6M | 508.6K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $64,000.00 | ★ $37,632,000.00 |
| Revenue This Year | $11,291.47 | $3.21 |
| Revenue Next Year | $74.30 | $9.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $0.85 | $2.15 |
| 52 Week High | $3.82 | $8.77 |
Technical Indicators
Market Signals| Indicator | CNTB | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 37.76 |
| Support Level | $0.85 | $2.34 |
| Resistance Level | $2.74 | $2.83 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 3.46 | 2.38 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.